CovidChloroV1, Main, Exploration, bibRecord, 000426

Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?

Identifieur interne : 000426 ( Main/Exploration ); précédent : 000425; suivant : 000427

Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?

Auteurs : Lucie Pothen [Belgique] ; Halil Yildiz [Belgique] ; Mathilde Mbouck Samnick [Royaume-Uni] ; Jean Cyr Yombi [Belgique]

Source :

Clinical rheumatology [ 1434-9949 ] ; 2021.

RBID : pubmed:33452660

Descripteurs français

KwdFr :
- Antiviraux (usage thérapeutique), Cardiotoxicité (étiologie), Essais contrôlés randomisés comme sujet (MeSH), Humains (MeSH), Hydroxychloroquine (effets indésirables), Hydroxychloroquine (usage thérapeutique), Lupus érythémateux disséminé (traitement médicamenteux), Maladies auto-immunes (traitement médicamenteux), Résultat thérapeutique (MeSH).
MESH :
- effets indésirables : Hydroxychloroquine.
- traitement médicamenteux : Lupus érythémateux disséminé, Maladies auto-immunes.
- usage thérapeutique : Antiviraux, Hydroxychloroquine.
- étiologie : Cardiotoxicité.
- Essais contrôlés randomisés comme sujet, Humains, Résultat thérapeutique.

English descriptors

KwdEn :
- Antiviral Agents (therapeutic use), Autoimmune Diseases (drug therapy), COVID-19 (drug therapy), Cardiotoxicity (etiology), Humans (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Lupus Erythematosus, Systemic (drug therapy), Randomized Controlled Trials as Topic (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , adverse effects : Hydroxychloroquine.
- chemical , therapeutic use : Antiviral Agents, Hydroxychloroquine.
- drug therapy : Autoimmune Diseases, COVID-19, Lupus Erythematosus, Systemic.
- etiology : Cardiotoxicity.
- Humans, Randomized Controlled Trials as Topic, Treatment Outcome.

Abstract

In the early stage of the COVID-19 pandemic, Belgian health authorities endorsed the interim guidelines for the treatment of COVID-19 pneumonia: hydroxychloroquine (HCQ) recommended for treatment of hospitalized patients with moderate to severe disease. As a growing number of patients were admitted, inevitably, our internal medicine team questioned the efficacy and safety of HCQ, especially with regard to cardiac side effects. In parallel with our concerns, data regarding the safety and efficacy of HCQ were published, with discordant results and debate in the medical community. Media coverage of the possible risks and benefits of HCQ use in COVID-19 also caused confusion amongst the public. In this Perspectives in Rheumatology article, we review the use and safety of HCQ in autoimmune disease and its putative efficacy and toxicity in COVID-19. Finally, we share our concern about the future of this widely used and inexpensive drug after the COVID-19 pandemic has passed.

DOI: 10.1007/s10067-020-05572-9
PubMed: 33452660
PubMed Central: PMC7810282

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000476
to stream Main, to step Curation: 000476

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?</title>
<author><name sortKey="Pothen, Lucie" sort="Pothen, Lucie" uniqKey="Pothen L" first="Lucie" last="Pothen">Lucie Pothen</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium. lucie.pothen@uclouvain.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yildiz, Halil" sort="Yildiz, Halil" uniqKey="Yildiz H" first="Halil" last="Yildiz">Halil Yildiz</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Samnick, Mathilde Mbouck" sort="Samnick, Mathilde Mbouck" uniqKey="Samnick M" first="Mathilde Mbouck" last="Samnick">Mathilde Mbouck Samnick</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine and Cardiology, Saint Georges Hospital, Blackshaw Road, London, SW17 OQT, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Internal Medicine and Cardiology, Saint Georges Hospital, Blackshaw Road, London, SW17 OQT</wicri:regionArea>
<wicri:noRegion>SW17 OQT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yombi, Jean Cyr" sort="Yombi, Jean Cyr" uniqKey="Yombi J" first="Jean Cyr" last="Yombi">Jean Cyr Yombi</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33452660</idno>
<idno type="pmid">33452660</idno>
<idno type="doi">10.1007/s10067-020-05572-9</idno>
<idno type="pmc">PMC7810282</idno>
<idno type="wicri:Area/Main/Corpus">000476</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000476</idno>
<idno type="wicri:Area/Main/Curation">000476</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000476</idno>
<idno type="wicri:Area/Main/Exploration">000476</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?</title>
<author><name sortKey="Pothen, Lucie" sort="Pothen, Lucie" uniqKey="Pothen L" first="Lucie" last="Pothen">Lucie Pothen</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium. lucie.pothen@uclouvain.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yildiz, Halil" sort="Yildiz, Halil" uniqKey="Yildiz H" first="Halil" last="Yildiz">Halil Yildiz</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Samnick, Mathilde Mbouck" sort="Samnick, Mathilde Mbouck" uniqKey="Samnick M" first="Mathilde Mbouck" last="Samnick">Mathilde Mbouck Samnick</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine and Cardiology, Saint Georges Hospital, Blackshaw Road, London, SW17 OQT, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Internal Medicine and Cardiology, Saint Georges Hospital, Blackshaw Road, London, SW17 OQT</wicri:regionArea>
<wicri:noRegion>SW17 OQT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yombi, Jean Cyr" sort="Yombi, Jean Cyr" uniqKey="Yombi J" first="Jean Cyr" last="Yombi">Jean Cyr Yombi</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical rheumatology</title>
<idno type="eISSN">1434-9949</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Autoimmune Diseases (drug therapy)</term>
<term>COVID-19 (drug therapy)</term>
<term>Cardiotoxicity (etiology)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (adverse effects)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Lupus Erythematosus, Systemic (drug therapy)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term>
<term>Cardiotoxicité (étiologie)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (effets indésirables)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Lupus érythémateux disséminé (traitement médicamenteux)</term>
<term>Maladies auto-immunes (traitement médicamenteux)</term>
<term>Résultat thérapeutique (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autoimmune Diseases</term>
<term>COVID-19</term>
<term>Lupus Erythematosus, Systemic</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cardiotoxicity</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lupus érythémateux disséminé</term>
<term>Maladies auto-immunes</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Cardiotoxicité</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the early stage of the COVID-19 pandemic, Belgian health authorities endorsed the interim guidelines for the treatment of COVID-19 pneumonia: hydroxychloroquine (HCQ) recommended for treatment of hospitalized patients with moderate to severe disease. As a growing number of patients were admitted, inevitably, our internal medicine team questioned the efficacy and safety of HCQ, especially with regard to cardiac side effects. In parallel with our concerns, data regarding the safety and efficacy of HCQ were published, with discordant results and debate in the medical community. Media coverage of the possible risks and benefits of HCQ use in COVID-19 also caused confusion amongst the public. In this Perspectives in Rheumatology article, we review the use and safety of HCQ in autoimmune disease and its putative efficacy and toxicity in COVID-19. Finally, we share our concern about the future of this widely used and inexpensive drug after the COVID-19 pandemic has passed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33452660</PMID>
<DateCompleted><Year>2021</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>40</Volume>
<Issue>4</Issue>
<PubDate><Year>2021</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Clinical rheumatology</Title>
<ISOAbbreviation>Clin Rheumatol</ISOAbbreviation>
</Journal>
<ArticleTitle>Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?</ArticleTitle>
<Pagination><MedlinePgn>1649-1657</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-020-05572-9</ELocationID>
<Abstract><AbstractText>In the early stage of the COVID-19 pandemic, Belgian health authorities endorsed the interim guidelines for the treatment of COVID-19 pneumonia: hydroxychloroquine (HCQ) recommended for treatment of hospitalized patients with moderate to severe disease. As a growing number of patients were admitted, inevitably, our internal medicine team questioned the efficacy and safety of HCQ, especially with regard to cardiac side effects. In parallel with our concerns, data regarding the safety and efficacy of HCQ were published, with discordant results and debate in the medical community. Media coverage of the possible risks and benefits of HCQ use in COVID-19 also caused confusion amongst the public. In this Perspectives in Rheumatology article, we review the use and safety of HCQ in autoimmune disease and its putative efficacy and toxicity in COVID-19. Finally, we share our concern about the future of this widely used and inexpensive drug after the COVID-19 pandemic has passed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pothen</LastName>
<ForeName>Lucie</ForeName>
<Initials>L</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-8424-0623</Identifier>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium. lucie.pothen@uclouvain.be.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yildiz</LastName>
<ForeName>Halil</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Samnick</LastName>
<ForeName>Mathilde Mbouck</ForeName>
<Initials>MM</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Cardiology, Saint Georges Hospital, Blackshaw Road, London, SW17 OQT, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yombi</LastName>
<ForeName>Jean Cyr</ForeName>
<Initials>JC</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, Université de Louvain (UCLouvain), 10 avenue Hippocrate, 1200, Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>01</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Clin Rheumatol</MedlineTA>
<NlmUniqueID>8211469</NlmUniqueID>
<ISSNLinking>0770-3198</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D066126" MajorTopicYN="N">Cardiotoxicity</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune disease</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword>
<Keyword MajorTopicYN="N">Toxicity</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>09</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>12</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>12</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>1</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>3</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>1</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>41</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33452660</ArticleId>
<ArticleId IdType="doi">10.1007/s10067-020-05572-9</ArticleId>
<ArticleId IdType="pii">10.1007/s10067-020-05572-9</ArticleId>
<ArticleId IdType="pmc">PMC7810282</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Pothen L, Yildiz H, De Greef J, Penaloza A, Beauloye C, Belkhir L, Yombi JC (2020) Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: clinical experience in a Belgian tertiary center. Travel Med Infect Dis 36:101788. https://doi.org/10.1016/j.tmaid.2020.101788</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101788</ArticleId>
<ArticleId IdType="pubmed">32540396</ArticleId>
<ArticleId IdType="pmcid">7290202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Schrezenmeier E, Dorner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155–166. https://doi.org/10.1038/s41584-020-0372-x</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0372-x</ArticleId>
<ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, da Mota LMH, Dos Santos Paiva E, Pileggi GCS, Sato EI, Reis A, Xavier RM, Provenza JR (2020) Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol 60(1):32. https://doi.org/10.1186/s42358-020-00134-8</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1186/s42358-020-00134-8</ArticleId>
<ArticleId IdType="pubmed">32517786</ArticleId>
<ArticleId IdType="pmcid">7282202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrom K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736–745. https://doi.org/10.1136/annrheumdis-2019-215089</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId>
<ArticleId IdType="pubmed">30926722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study (1995) Am J Med 98(2):156–168. https://doi.org/10.1016/s0002-9343(99)80399-4</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9343(99)80399-4</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A (2016) Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 5(1). https://doi.org/10.1161/JAHA.115.002867</Citation>
</Reference>
<Reference><Citation>Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 11(4):R109. https://doi.org/10.1186/ar2764</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1186/ar2764</ArticleId>
<ArticleId IdType="pubmed">19604357</ArticleId>
<ArticleId IdType="pmcid">2745791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bultink IE, Hamann D, Seelen MA, Hart MH, Dijkmans BA, Daha MR, Voskuyl AE (2006) Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res Ther 8(6):R183. https://doi.org/10.1186/ar2095</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1186/ar2095</ArticleId>
<ArticleId IdType="pubmed">17166254</ArticleId>
<ArticleId IdType="pmcid">1794530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35(3):387–393</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18260176</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rolain JM, Colson P, Raoult D (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30(4):297–308. https://doi.org/10.1016/j.ijantimicag.2007.05.015</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2007.05.015</ArticleId>
<ArticleId IdType="pubmed">17629679</ArticleId>
<ArticleId IdType="pmcid">7126847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Jorge A, Ung C, Young LH, Melles RB, Choi HK (2018) Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol 14(12):693–703. https://doi.org/10.1038/s41584-018-0111-8</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0111-8</ArticleId>
<ArticleId IdType="pubmed">30401979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Fiehn C, Ness T, Weseloh C, Specker C, Hadjiski D, Detert J, Kruger K, Pharmakotherapie DGK (2020) Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. Z Rheumatol. https://doi.org/10.1007/s00393-020-00785-4</Citation>
</Reference>
<Reference><Citation>Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, Suter W (2004) Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484(1):41–48. https://doi.org/10.1016/j.ejphar.2003.11.003</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2003.11.003</ArticleId>
<ArticleId IdType="pubmed">14729380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chen CY, Wang FL, Lin CC (2006) Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 44(2):173–175. https://doi.org/10.1080/15563650500514558</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1080/15563650500514558</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z (2018) Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol 36(4):545–551</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29652656</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Risch HA (2020) Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped up immediately as key to the pandemic crisis. Am J Epidemiol 189(11):1218–1226. https://doi.org/10.1093/aje/kwaa093</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwaa093</ArticleId>
<ArticleId IdType="pubmed">32458969</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71(15):732–739. https://doi.org/10.1093/cid/ciaa237</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId>
<ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Funnell SGP, Dowling WE, Munoz-Fontela C, Gsell PS, Ingber DE, Hamilton GA, Delang L, Rocha-Pereira J, Kaptein S, Dallmeier KH, Neyts J, Rosenke K, de Wit E, Feldmann H, Maisonnasse P, Le Grand R, Frieman MB, Coleman CM (2020) Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nat Commun 11(1):4253. https://doi.org/10.1038/s41467-020-17907-w</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17907-w</ArticleId>
<ArticleId IdType="pubmed">32848158</ArticleId>
<ArticleId IdType="pmcid">7450055</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhang J, Tecson KM, McCullough PA (2020) Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med 21(3):315–319. https://doi.org/10.31083/j.rcm.2020.03.126</Citation>
<ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm.2020.03.126</ArticleId>
<ArticleId IdType="pubmed">33070537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhaowei Chen JH, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Ben H, Zhang Z (2020) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRixv. https://doi.org/10.1101/2020.03.22.20040758</Citation>
</Reference>
<Reference><Citation>Nikolas Bernaola RM, Bernaola A, Lara A, Carballo C, Larranaga P, Bielza C (2020) Observational study of the efficiency of treatments in patients hospitalized with covid-19 in Madrid. MedRixv. https://doi.org/10.1101/2020.07.17.20155960</Citation>
</Reference>
<Reference><Citation>Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honore S, Stein A, Jacquier A, Deharo JC, Chabriere E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D (2020) Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 35:101738. https://doi.org/10.1016/j.tmaid.2020.101738</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101738</ArticleId>
<ArticleId IdType="pubmed">32387409</ArticleId>
<ArticleId IdType="pmcid">7199729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emilie Sbidian JJ, Lemaitre G, Mayer I, Bernaux M, Gramfort A, Lapidus N, Paris N, Neuraz A, Lerner I, Garcelon N, Rance B, Grisel O, Moreau T, Bellamine A, Wolkenstein P, Varoquaux G, Caumes E, Lavielle M, Dessap AM, Audureau E (2020) Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. MedRixv. https://doi.org/10.1101/2020.06.16.20132597</Citation>
</Reference>
<Reference><Citation>Yu B, Li C, Chen P, Li J, Jiang H, Wang DW (2020) Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Sci China Life Sci. https://doi.org/10.1007/s11427-020-1782-1</Citation>
</Reference>
<Reference><Citation>Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, van Ierssel S, Duysburgh E, Van Oyen H, Wyndham-Thomas C, Van Beckhoven D, Belgian Collaborative Group on C-HS (2020) Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents 56(4):106144. https://doi.org/10.1016/j.ijantimicag.2020.106144</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106144</ArticleId>
<ArticleId IdType="pubmed">32853673</ArticleId>
<ArticleId IdType="pmcid">7444610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Di Castelnuovo A, Bonaccio M, Costanzo S, Gialluisi A, Antinori A, Berselli N, Blandi L, Bruno R, Cauda R, Guaraldi G, My I, Menicanti L, Parruti G, Patti G, Perlini S, Santilli F, Signorelli C, Stefanini GG, Vergori A, Abdeddaim A, Ageno W, Agodi A, Agostoni P, Aiello L, Al Moghazi S, Aucella F, Barbieri G, Bartoloni A, Bologna C, Bonfanti P, Brancati S, Cacciatore F, Caiano L, Cannata F, Carrozzi L, Cascio A, Cingolani A, Cipollone F, Colomba C, Crisetti A, Crosta F, Danzi GB, D’Ardes D, de Gaetano Donati K, Di Gennaro F, Di Palma G, Di Tano G, Fantoni M, Filippini T, Fioretto P, Fusco FM, Gentile I, Grisafi L, Guarnieri G, Landi F, Larizza G, Leone A, Maccagni G, Maccarella S, Mapelli M, Maragna R, Marcucci R, Maresca G, Marotta C, Marra L, Mastroianni F, Mengozzi A, Menichetti F, Milic J, Murri R, Montineri A, Mussinelli R, Mussini C, Musso M, Odone A, Olivieri M, Pasi E, Petri F, Pinchera B, Pivato CA, Pizzi R, Poletti V, Raffaelli F, Ravaglia C, Righetti G, Rognoni A, Rossato M, Rossi M, Sabena A, Salinaro F, Sangiovanni V, Sanrocco C, Scarafino A, Scorzolini L, Sgariglia R, Simeone PG, Spinoni E, Torti C, Trecarichi EM, Vezzani F, Veronesi G, Vettor R, Vianello A, Vinceti M, De Caterina R, Iacoviello L, RISk CO-, Treatments c (2020) Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis 30(11):1899–1913. https://doi.org/10.1016/j.numecd.2020.07.031</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2020.07.031</ArticleId>
<ArticleId IdType="pubmed">32912793</ArticleId>
<ArticleId IdType="pmcid">7833278</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M, Henry Ford C-TF (2020) Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 97:396–403. https://doi.org/10.1016/j.ijid.2020.06.099</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.06.099</ArticleId>
<ArticleId IdType="pubmed">32623082</ArticleId>
<ArticleId IdType="pmcid">7330574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, Honore S, Gaubert JY, Fournier PE, Tissot-Dupont H, Chabriere E, Stein A, Deharo JC, Fenollar F, Rolain JM, Obadia Y, Jacquier A, La Scola B, Brouqui P, Drancourt M, Parola P, Raoult D, force IC-T (2020) Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med Infect Dis 36:101791. https://doi.org/10.1016/j.tmaid.2020.101791</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2020.101791</ArticleId>
<ArticleId IdType="pubmed">32593867</ArticleId>
<ArticleId IdType="pmcid">7315163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ayerbe L, Risco-Risco C, Ayis S (2020) The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. Intern Emerg Med 15(8):1501–1506. https://doi.org/10.1007/s11739-020-02505-x</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1007/s11739-020-02505-x</ArticleId>
<ArticleId IdType="pubmed">32997237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, Brinkman K, Hassing RJ, Dofferhoff A, El Moussaoui R, Hermanides G, Ellerbroek J, Bokhizzou N, Visser H, van den Berge M, Bax H, Postma DF, Groeneveld PHP (2020) Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2020.09.1460</Citation>
</Reference>
<Reference><Citation>Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, Bednarz U, Marafelias M, Berry SM, Berry NS, Mathura S, Sawczuk IS, Biran N, Go RC, Sperber S, Piwoz JA, Balani B, Cicogna C, Sebti R, Zuckerman J, Rose KM, Tank L, Jacobs LG, Korcak J, Timmapuri SL, Underwood JP, Sugalski G, Barsky C, Varga DW, Asif A, Landolfi JC, Goldberg SL (2020) Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study. PLoS One 15(8):e0237693. https://doi.org/10.1371/journal.pone.0237693</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237693</ArticleId>
<ArticleId IdType="pubmed">32790733</ArticleId>
<ArticleId IdType="pmcid">7425928</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA (2020) Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 323(24):2493–2502. https://doi.org/10.1001/jama.2020.8630</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.8630</ArticleId>
<ArticleId IdType="pubmed">7215635</ArticleId>
<ArticleId IdType="pmcid">7215635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Shailendra Singh AK, Chowdhry M, Chatterjee A (2020) Outcomes of hydroxychloroquine treatment among hospitalized COVID-19 patients in the United States- real-world evidence from a federated electronic medical record network. MedRixv. https://doi.org/10.1101/2020.05.12.20099028</Citation>
</Reference>
<Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW (2020) Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 382(25):2411–2418. https://doi.org/10.1056/NEJMoa2012410</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2012410</ArticleId>
<ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020) RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. https://doi.org/10.1016/S0140-6736(20)31180-6</Citation>
</Reference>
<Reference><Citation>Peter Horby MM, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse A, Felton T, Williams J, Faccenda J, Underwood J, Baillie K, Chappell L, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Martin J Landray RECOVERY (2020) Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. MedRxiv. https://doi.org/10.1101/2020.07.15.20151852</Citation>
</Reference>
<Reference><Citation>Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, de Barros ESPGM, Tramujas L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi de Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O, Coalition Covid-19 Brazil II (2020) Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2019014</Citation>
</Reference>
<Reference><Citation>WHO Solidarity trial Consortium HP, Peto R et al (2020) Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. MedRixv. https://doi.org/10.1101/2020.10.15.20209817</Citation>
</Reference>
<Reference><Citation>Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM, National Heart L, Blood Institute PCTN (2020) Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2020.22240</Citation>
</Reference>
<Reference><Citation>Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu CY, Rubinstein SM, Lee BJ, Choueiri TK, de Lima Lopes G Jr, Grivas P, Painter CA, Rini BI, Thompson MA, Arcobello J, Bakouny Z, Doroshow DB, Egan PC, Farmakiotis D, Fecher LA, Friese CR, Galsky MD, Goel S, Gupta S, Halfdanarson TR, Halmos B, Hawley JE, Khaki AR, Lemmon CA, Mishra S, Olszewski AJ, Pennell NA, Puc MM, Revankar SG, Schapira L, Schmidt A, Schwartz GK, Shah SA, Wu JT, Xie Z, Yeh AC, Zhu H, Shyr Y, Lyman GH, Warner JL, Covid CC (2020) Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov 10(10):1514–1527. https://doi.org/10.1158/2159-8290.CD-20-0941</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0941</ArticleId>
<ArticleId IdType="pubmed">32699031</ArticleId>
<ArticleId IdType="pmcid">7541683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Dauby N, Bottieau E (2020) The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment? Int J Infect Dis. https://doi.org/10.1016/j.ijid.2020.10.032</Citation>
</Reference>
<Reference><Citation>Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS (2020) Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 5(9):1036–1041. https://doi.org/10.1001/jamacardio.2020.1834</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1834</ArticleId>
<ArticleId IdType="pubmed">32936252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gerard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, Chouchana L, Rocher F, Drici MD, French Network of Pharmacovigilance C (2020) "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie 75(4):371–379. https://doi.org/10.1016/j.therap.2020.05.002</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2020.05.002</ArticleId>
<ArticleId IdType="pubmed">32418730</ArticleId>
<ArticleId IdType="pmcid">7204701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gasperetti A, Biffi M, Duru F, Schiavone M, Ziacchi M, Mitacchione G, Lavalle C, Saguner A, Lanfranchi A, Casalini G, Tocci M, Fabbricatore D, Salghetti F, Mariani MV, Busana M, Bellia A, Cogliati CB, Viale P, Antinori S, Galli M, Galie N, Tondo C, Forleo GB (2020) Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. Europace. https://doi.org/10.1093/europace/euaa216</Citation>
</Reference>
<Reference><Citation>Bhatla A, Mayer MM, Adusumalli S, Hyman MC, Oh E, Tierney A, Moss J, Chahal AA, Anesi G, Denduluri S, Domenico CM, Arkles J, Abella BS, Bullinga JR, Callans DJ, Dixit S, Epstein AE, Frankel DS, Garcia FC, Kumareswaram R, Nazarian S, Riley MP, Santangeli P, Schaller RD, Supple GE, Lin D, Marchlinski F, Deo R (2020) COVID-19 and cardiac arrhythmias. Heart Rhythm 17(9):1439–1444. https://doi.org/10.1016/j.hrthm.2020.06.016</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2020.06.016</ArticleId>
<ArticleId IdType="pubmed">32585191</ArticleId>
<ArticleId IdType="pmcid">7307518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kunutsor SK, Laukkanen JA (2020) Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med 52(7):345–353. https://doi.org/10.1080/07853890.2020.1790643</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1790643</ArticleId>
<ArticleId IdType="pubmed">32643418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH (2020) A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 383(6):517–525. https://doi.org/10.1056/NEJMoa2016638</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2016638</ArticleId>
<ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mitja O, Corbacho-Monne M, Ubals M, Alemany A, Suner C, Tebe C, Tobias A, Penafiel J, Ballana E, Perez CA, Admella P, Riera-Marti N, Laporte P, Mitja J, Clua M, Bertran L, Sarquella M, Gavilan S, Ara J, Argimon JM, Cuatrecasas G, Canadas P, Elizalde-Torrent A, Fabregat R, Farre M, Forcada A, Flores-Mateo G, Lopez C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quinones C, Ramirez-Viaplana F, Reyes-Uruena J, Riveira-Munoz E, Ruiz L, Sanz S, Sentis A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, Gonzalez-Beiras C, Clotet B, Group BC-P-CR (2020) A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2021801</Citation>
</Reference>
<Reference><Citation>Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK, the P, Treatment of C-WHI (2020) Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.6319</Citation>
</Reference>
<Reference><Citation>Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ, 2nd (2020) Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol 2 (11):e689-e697. doi: https://doi.org/10.1016/S2665-9913(20)30305-2</Citation>
</Reference>
<Reference><Citation>Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, Wu B, Zhang A, Su L, Hou X, Song S, Li H, Zhou W, Zhou T, Huang Q, Chu A, Braunstein Z, Rao X, Ye C, Dong L (2020) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2(9):e557–e564. https://doi.org/10.1016/S2665-9913(20)30227-7</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30227-7</ArticleId>
<ArticleId IdType="pubmed">32838309</ArticleId>
<ArticleId IdType="pmcid">7333992</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ferreira A, Oliveira ESA, Bettencourt P (2020) Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol. https://doi.org/10.1002/jmv.26286</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Belgique</li>
<li>Royaume-Uni</li>
</country>
<region><li>Région de Bruxelles-Capitale</li>
</region>
<settlement><li>Bruxelles</li>
</settlement>
</list>
<tree><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Pothen, Lucie" sort="Pothen, Lucie" uniqKey="Pothen L" first="Lucie" last="Pothen">Lucie Pothen</name>
</region>
<name sortKey="Yildiz, Halil" sort="Yildiz, Halil" uniqKey="Yildiz H" first="Halil" last="Yildiz">Halil Yildiz</name>
<name sortKey="Yombi, Jean Cyr" sort="Yombi, Jean Cyr" uniqKey="Yombi J" first="Jean Cyr" last="Yombi">Jean Cyr Yombi</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Samnick, Mathilde Mbouck" sort="Samnick, Mathilde Mbouck" uniqKey="Samnick M" first="Mathilde Mbouck" last="Samnick">Mathilde Mbouck Samnick</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000426 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000426 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33452660
   |texte=   Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33452660" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?

Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki